There is no doubt that there are tough times ahead for many of the big Pharma companies, there are no new blockbusters drugs on the horizon and a number of ‘previous’ blockbusters are coming off patent in 2012 including Viagra. The loss of exclusivity for these products means maintaining the huge profit margins they have come to demand will become increasingly difficult.
In fact, numerous actions have been taking place through international regulations including changes to the conditions of credit card merchants in the sale of pharmaceuticals, and we have no doubt that many of these have been driven by the Pharmaceutical giants to try to help to maintain their ‘needs.’ However the upshot is that a number of generics of popular now off patent drugs are going to be made available soon and this will drive down costs to the consumers.
IAS’s policy has always been one of providing the original drugs, we see this as an essential requirement because sometimes the ‘devil is in the detail’ and if one wants the best possible beneficial results, (as proven in the original trials) then the original drug should be available as a choice, (that is certainly true in the case of Can-C™ eye-drops for example). However, we have also considered that in these financially difficult times making quality generics available alongside the original brands is necessary. So you may have noticed that there have been a number of new generics such as Anastro Pro generic Low dose form of Arimidex and very shortly Adra Pro a generic version of the recently discontinued Adrafinil joining the IAS line up, watch this space as there will be more to come.
We hope that these changes will give you choices to match your budget and your health care requirements.